{"filing":{"accession_number":"0001159036-26-000088","cik":"0001159036","ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"halo-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000088/halo-20260630.htm"},"events":[{"id":15834,"run_id":14124,"accession_number":"0001159036-26-000088","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer effective June 30, 2026. The principal disclosed action is a named executive officer leaving her role. While the filing mentions \"an update to its senior management structure,\" the substantive disclosure centers on Ms. Caudill's departure, making this an exec_departure event. The COO position is material to investor assessment of company leadership.","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13737,"accession_number":"0001159036-26-000088","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer effective June 30, 2026. The principal disclosed action is a named executive officer leaving her role. While the filing mentions \"an update to its senior management structure,\" the substantive disclosure centers on Ms. Caudill's departure, making this an exec_departure event. The COO position is material to investor assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:51.114430+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13737,"accession_number":"0001159036-26-000088","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer effective June 30, 2026. The principal disclosed action is a named executive officer leaving her role. While the filing mentions \"an update to its senior management structure,\" the substantive disclosure centers on Ms. Caudill's departure, making this an exec_departure event. The COO position is material to investor assessment of company leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:51.114430+00:00","company_name":"HALOZYME THERAPEUTICS, INC.","ticker":"HALO","filing_date":"2026-07-02"}]}